Search

Your search keyword '"Tallini, G"' showing total 17 results
Start Over Author "Tallini, G" Publisher elsevier bv
17 results on '"Tallini, G"'

1. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer

Author

Nannini, M., primary, Repaci, A., additional, Nigro, M.C., additional, Colapinto, A., additional, Vicennati, V., additional, Maloberti, T., additional, Gruppioni, E., additional, Altimari, A., additional, Solaroli, E., additional, Lodi Rizzini, E., additional, Monari, F., additional, De Leo, A., additional, Damiani, S., additional, Pagotto, U., additional, Pantaleo, M.A., additional, de Biase, D., additional, and Tallini, G., additional

Published
2023
Full Text
View/download PDF

5. The role of clinical and molecular characteristics in low grade gliomas

Author

Mura, A., primary, Franceschi, E., additional, Minichillo, S., additional, Tosoni, A., additional, Fioravanti, A., additional, Talacchi, A., additional, Volpin, L., additional, Tallini, G., additional, De Biase, D., additional, Visani, M., additional, Degli Esposti, R., additional, Genestreti, G., additional, Pizzolitto, S., additional, Agati, R., additional, Bortolotti, C., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

6. The role of treatments in IDH mutant molecular astrocytomas

Author

Minichillo, S., primary, Franceschi, E., additional, Mura, A., additional, Tosoni, A., additional, Tallini, G., additional, Pession, A., additional, Foschini, M., additional, Bortolotti, C., additional, Danieli, D., additional, Talacchi, A., additional, Cirillo, L., additional, Di Battista, M., additional, Genestreti, G., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

7. IDH wild type low grade gliomas: Who seeks shall find

Author

Mandrioli, A., primary, Franceschi, E., additional, Minichillo, S., additional, Mura, A., additional, Tosoni, A., additional, De Biase, D., additional, Zunarelli, E., additional, Lanza, G., additional, Bartolini, D., additional, Silini, E.M., additional, Tallini, G., additional, Cirillo, L., additional, Bortolotti, C., additional, Danieli, D., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

8. The role of clinical characteristics in low grade gliomas in molecular era

Author

Mura, A., primary, Franceschi, E., additional, Minichillo, S., additional, Mandrioli, A., additional, Tosoni, A., additional, Fioravanti, A., additional, Talacchi, A., additional, Volpin, L., additional, Tallini, G., additional, De Biase, D., additional, Agati, R., additional, Pizzolitto, S., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

9. Prognostic factors for IDH mutant molecular astrocytomas

Author

Minichillo, S., primary, Franceschi, E., additional, Mura, A., additional, Mandrioli, A., additional, Tosoni, A., additional, Tallini, G., additional, Pession, A., additional, Foschini, M.P., additional, Bortolotti, C., additional, Danieli, D., additional, Talacchi, A., additional, Cirillo, L., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

10. Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Author

Franceschi, E., primary, De Biase, D., additional, Paccapelo, A., additional, Reni, M., additional, Mura, A., additional, Tallini, G., additional, Bortolotti, C., additional, Volpin, L., additional, Marucci, G., additional, Cirillo, L., additional, Pession, A., additional, Ghimenton, C., additional, Poggi, R., additional, Bartolini, S., additional, Albini Riccioli, L., additional, Tosoni, A., additional, Degli Esposti, C., additional, Danieli, D., additional, Genestreti, G., additional, and Brandes, A.A., additional

Published
2016
Full Text
View/download PDF

11. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients

Author

Cappuzzo, F., primary, Tallini, G., additional, Finocchiaro, G., additional, Wilson, R.S., additional, Ligorio, C., additional, Giordano, L., additional, Toschi, L., additional, Incarbone, M., additional, Cavina, R., additional, Terracciano, L., additional, Roncalli, M., additional, Alloisio, M., additional, Varella-Garcia, M., additional, Franklin, W.A., additional, and Santoro, A., additional

Published
2010
Full Text
View/download PDF

12. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

Author

Cappuzzo, F., primary, Toschi, L., additional, Tallini, G., additional, Ceresoli, G.L., additional, Domenichini, I., additional, Bartolini, S., additional, Finocchiaro, G., additional, Magrini, E., additional, Metro, G., additional, Cancellieri, A., additional, Trisolini, R., additional, Crino, L., additional, Bunn, P.A., additional, Santoro, A., additional, Franklin, W.A., additional, Varella-Garcia, M., additional, and Hirsch, F.R., additional

Published
2006
Full Text
View/download PDF

13. Clinical experience with gefitinib: An update

Author

CAPPUZZO, F, primary, FINOCCHIARO, G, additional, METRO, G, additional, BARTOLINI, S, additional, MAGRINI, E, additional, CANCELLIERI, A, additional, TRISOLINI, R, additional, CASTALDINI, L, additional, TALLINI, G, additional, and CRINO, L, additional

Published
2006
Full Text
View/download PDF

14. HMGI-C and HMGI(Y) Immunoreactivity Correlates with Cytogenetic Abnormalities in Lipomas, Pulmonary Chondroid Hamartomas, Endometrial Polyps, and Uterine Leiomyomas and is Compatible with Rearrangement of the HMGI-C and HMGI(Y) Genes

Author

Tallini, G, primary, Vanni, R, additional, Manfioletti, G, additional, Kazmierczak, B, additional, Faa, G, additional, Pauwels, P, additional, Bullerdiek, J, additional, Giancotti, V, additional, Van Den Berghe, H, additional, and Cin, P Dal, additional

Published
2000
Full Text
View/download PDF

16. The clinical and prognostic role of ALK in glioblastoma

Author

Stefania Bartolini, Giovanni Tallini, Raffaele Lodi, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Dario de Biase, Michela Visani, Alba A. Brandes, Vincenzo Di Nunno, Enrico Franceschi, Franceschi E., De Biase D., Di Nunno V., Pession A., Tosoni A., Gatto L., Tallini G., Visani M., Lodi R., Bartolini S., and Brandes A.A.

Subjects
Adult, Male, 0301 basic medicine, Monosomy, Prognosi, In situ hybridization, GBM, Pathology and Forensic Medicine, Brain Neoplasm, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Biomarkers, Tumor, medicine, Humans, Anaplastic lymphoma kinase, Overall survival, Anaplastic Lymphoma Kinase, Aged, Retrospective Studies, Prognostic factor, Polysomy, biology, Brain Neoplasms, business.industry, Wild type, Cell Biology, Middle Aged, Prognosis, medicine.disease, 030104 developmental biology, Isocitrate dehydrogenase, ALK, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Immunohistochemistry, Female, Antibody, Glioblastoma, business, Human
Abstract

Background anaplastic lymphoma kinase (ALK) overexpression and gene alterations have been detected in several malignancies, with prognostic and therapeutic implications. However, few studies investigated the correlation between ALK altered expression and prognosis in patients with glioblastoma (GBM). Methods We performed an evaluation of ALK overexpression and structural/quantitative chromosome alterations through immune-histochemical assay (IHC with D5F3 antibody) and fluorescent in situ hybridization (FISH) in patients with isocitrate dehydrogenase (IDH) wild type (wt) GBM. Assuming an ALK overexpression in 20 % of patients we planned a sample of 44 patients to achieve a probability of 90 % to include from 10 % to 30 % of patients with ALK alterations. Results We evaluated 44 patients with IDH wt GBM, treated in our institution and dead due to GBM progression in 2017. ALK overexpression obtained by a composed score (the product of IHC intensity staining and rate of positive cells) was observed in 19 (43 %) patients. FISH analysis showed that 11 patients (25 %) had gene deletion, 2 patients (4.5 %) had monosomy and one patient (2.3 %) presented polysomy. Only one patient (2.3 %) demonstrated ALK rearrangement. There was no statistical difference in median OS between patients with ALK-positive (mOS = 18.9 months) and ALK-negative IHC (mOS = 18.0 months). Conclusion We identified some rare previously unreported alterations of ALK gene in patients with IDH wt GBM. In these patients, the ALK overexpression does not influences survival.

Published
2021

17. BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas

Author

Patrizia Riguzzi, Lilia Volpi, Ilaria Naldi, Agostino Baruzzi, Paolo Tinuper, Gianluca Marucci, Federica Marliani, Marco Giulioni, Francesca Bisulli, Dario de Biase, Guido Rubboli, Roberto Michelucci, Francesco Toni, Giovanni Tallini, Matteo Martinoni, Martinoni, M., Marucci, G., De Biase, D., Rubboli, G., Volpi, L., Riguzzi, P., Marliani, F., Toni, F., Naldi, I., Bisulli, F., Tinuper, P., Michelucci, R., Baruzzi, A., Tallini, G., and Giulioni, M.

Subjects
Adult, Male, Proto-Oncogene Proteins B-raf, Drug Resistant Epilepsy, Pathology, medicine.medical_specialty, Adolescent, Seizure outcome, Neocortex, medicine.disease_cause, Neurosurgical Procedures, Focal cortical dysplasia, Young Adult, Epilepsy, Epilepsy surgery, Seizures, Physiology (medical), medicine, Seizure control, Humans, Age of Onset, Child, Retrospective Studies, Ganglioglioma, Mutation, Brain Neoplasms, business.industry, BRAF V600E mutation, General Medicine, Middle Aged, Pharmacoresistant epilepsy, Cortical dysplasia, Prognosis, medicine.disease, BRAF V600E, Treatment Outcome, Epilepsy, Temporal Lobe, Neurology, Malformations of Cortical Development, Group I, Concomitant, Female, Surgery, Neurology (clinical), business
Abstract

The aim of this study was to verify the presence of BRAF mutations in a series of six patients affected by drug-resistant focal epilepsy associated with neocortical posterior temporal gangliogliomas (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of epilepsy and represent the most common tumor in young patients undergoing surgery for intractable focal epilepsy. BRAF mutations have been identified in up to 50% of GG. Interestingly, these six patients shared a specific anatomical posterior temporal site. In all patients, histological examination confirmed the diagnosis of GG, and two were also associated with a focal cortical dysplasia (FCD) type IIa. BRAF mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of Patient 2 showed a concomitant BRAF V600E mutation. All patients but one (83.3%) achieved Engel Class Ia seizure control. The patient carrying a concomitant BRAF mutation in GG and FCD fell into Engel Class II. Further analyses will be required in order to better understand the meaning of BRAF mutations in epilepsy-associated tumors and FCD and their possible role as a prognostic seizure outcome and tumor behavior marker.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results